Table 1.

Least squares means change from baseline in fasting plasma glucose (mg/dL) and changes from baseline in weighted mean glucose at 2 weeks

Endpoint	Timepoint	Treatment	n	Least squaresMean change from baseline	Treatment comparison	Mean difference	90% CI
Fasting plasma glucose	Day 3	MK‐8666 500 mg	18	33.3	MK‐8666 500 mg vs. placebo	37.2	(27.4, 46.9)
		MK‐8666 150 mg	18	21.0	MK‐8666 150 mg vs. placebo	24.9	(15.2, 34.7)
		MK‐8666 50 mg	9	10.5	MK‐8666 50 mg vs. placebo	14.4	(2.5, 26.4)
		Placebo	18	−3.9		—
	Day 7	MK‐8666 500 mg	18	39.4	MK‐8666 500 mg vs. placebo	45.1	(32.1, 58.1)
		MK‐8666 150 mg	18	30.2	MK‐8666 150 mg vs. placebo	36.0	(23.0, 49.0)
		MK‐8666 50 mg	9	28.9	MK‐8666 50 mg vs. placebo	34.7	(18.8, 50.6)
		Placebo	18	−5.7		—
	Day 14	MK‐8666 500 mg	18	55.6	MK‐8666 500 mg vs. placebo	56.2	(40.2, 72.2)
		MK‐8666 150 mg	18	42.3	MK‐8666 150 mg vs. placebo	42.9	(26.9, 58.9)
		MK‐8666 50 mg	9	28.5	MK‐8666 50 mg vs. placebo	29.1	(9.5, 48.7)
		Placebo	18	−0.6		—
	Day 15	MK‐8666 500 mg	18	56.0	MK‐8666 500 mg vs. placebo	54.1	(38.1, 70.0)
		MK‐8666 150 mg	18	37.9	MK‐8666 150 mg vs. placebo	36.0	(20.0, 51.9)
		MK‐8666 50 mg	9	32.8	MK‐8666 50 mg vs. placebo	30.8	(11.3, 50.3)
		Placebo	18	2.0		—
24‐H weighted mean glucose (mg/dL)	Day 14	MK‐8666 500 mg	18	45.4	MK‐8666 500 mg vs. placebo	48.8	(35.6, 62.0)
		MK‐8666 150 mg	18	27.3	MK‐8666 150 mg vs. placebo	30.6	(17.4, 43.8)
		MK‐8666 50 mg	9	19.0	MK‐8666 50 mg vs. placebo	22.3	(6.2, 38.4)
		Placebo	17a	−3.3		—

WMG, weighted mean glucose.

Least squares means and confidence intervals from a constrained longitudinal data analysis model.

^aData from one patient at Day 14 in the placebo group is missing, as the patient had to leave the study site for personal reasons.